ABRYSVO, a bivalent vaccine, maintained consistently high protective efficacy for both RSV A and RSV B disease through two seasons after a single dose. ABRYSVO efficacy was 77.8% against RSV lower ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Active immunization of individuals 18 years of age and older for the prevention of LRTD ...

Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion. Click here to find out why PFE stock is a Buy.

(RTTNews) - Pfizer (PFE) announced the European Commission has issued a decision amending the marketing authorization for ABRYSVO, the company's bivalent respiratory syncytial virus prefusion F ...

Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74 ACIP recommends adults 50–59 years of age who are at increased risk of severe RSV ...

Despite facing substantial headwinds, Pfizer's strategic pivot away from pandemic-related products is showing early signs of success. The company's second-quarter 2025 results revealed a 10% year-over ...

Pfizer's strong Q2 results, high dividend yield, and bullish chart fuel optimism despite patent losses and rising competition ...

Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...

Pfizer and Bristol Myers Squibb are trading for less than $50 per share. Despite patent cliffs and other issues they face, ...